TC Development

FIMM Technology Centre plays a critical role in sustaining and advancing cutting-edge technologies that directly support the strategic goals and scientific mission of FIMM.
Our strategy

We continuously assess and refine our service portfolio to ensure alignment with the evolving needs of the life science research community. This ongoing process includes evaluating the relevance, performance, and structure of our offerings—making strategic updates or phase-outs when necessary. 

Driving forward our next phase of development

Our current efforts are focused on developing enhanced multi-unit and multi-omics workflows to deliver greater value and innovation to our users. 

To enhance service accessibility and user experience, we are actively developing our "one-stop shop" capabilities. This initiative is designed to streamline access for new customers, industry partners, and researchers—particularly those managing large-scale, complex projects involving multiple data types. Our goal is to simplify the customer journey and support seamless integration across our service portfolio.

Our commitment to lifelong learning and capability building

Highly skilled technology specialists are critical to maintaining operational excellence, ensuring our platforms remain at the cutting edge of science, and preserving key technological expertise within core facilities. To secure this long-term capability, we are actively collaborating locally with HiLIFE and nationally with Biocenter Finland to establish a dedicated career track and implement a structured training program for core facility personnel. This initiative strengthens talent retention, supports innovation, and ensures continuity in high-impact scientific services.

Here’s a snapshot of the major milestones driving our progress:

2025
  • 2025 Biodata unit established
  • 16-plex Immunofluorescence for tissue (DMMP)
  • Metabolomics unit transferred to Faculty of Medicine
  • Two genomics units at Meilahti campus merged
  • Single cell sample preparation laboratory opened at HiPREP
  • Lighthouse status of Finnish Research Council to EuroBioImaging Finland (HCA)
2024
  • More than 35 000 DSRT (Drug Sensitivity and Resistance Testing) plates have been prepared since 2011
2023
  • HiPrep merged with EV (Extracellular Vesicles) Core
2022
  • First long read sequencing runs (FIMM Genomics)
2021
  • HCA joined Euro-Bioimaging as part of FIAM (Finnish Infrastructure for Advanced Microscopy)
2020
  • HiPREP was established
  • Spatial transcriptomics at Single-Cell Analytics
  • HCA and SCA co-developed activities through FIRI2020 Single Cell Competence Center in collaboration with Immuno Diagnostic, Leica, PerkinElmer and UPM
  • Venetoclax clinical trial
  • HTB joined EU-OpenScreen consortium
2019
  • VEIL.AI spin-off was founded (IT)

     

2018
  • High throughput flow cytometry introduced (HTB)

     

2017
  • FIMM High Content Imaging and Analysis Unit (HCA) established
  • FIMM Sample Storage expanded its capacity to 2.3 million sample vials

     

2016
  • HUB merged as a part of the Helsinki Biobank
  • SCA and EV Core established

     

2015
  • First large-scale compound screening project
2014
  • HUB and FHRB registered as biobanks in accordance with the Biobank Act
2012
  • HTB established (Chemical Biology and RNAi units were established in 2010 and merged into HTB in 2012)
2011
  • Helsinki Urological Biobank (HUB) and Finnish Hematology Registry and Clinical Biobank (FHRB) sample and data collection research projects established
  • First clinical sample case of personalized medicine
2010
  • Launch of RNAseq services
  •  Chemical Biology and RNAi units established
2009
  • FIMM Sample Storage purchased the first liquid nitrogen based freezers
2008
  • NGS services on Solexa up and running
  • FIMM IT unit established